AMGN logo

AMGN
AMGEN Inc.

14,785
Mkt Cap
$189.67B
Volume
2.73M
52W High
$391.29
52W Low
$261.43
PE Ratio
24.72
AMGN Fundamentals
Price
$353.28
Prev Close
$351.85
Open
$354.90
50D MA
$362.61
Beta
0.52
Avg. Volume
3.05M
EPS (Annual)
$14.23
P/B
21.90
Rev/Employee
$1.17M
$223,708.02
Loading...
Loading...
News
all
press releases
Zai Lab Stock Gains 8% Over Clinical Trial Collaboration With Amgen
(RTTNews) - Shares of Zai Lab Limited (ZLAB) are moving up about 8 percent on Wednesday morning trading after the company announced a global clinical trial collaboration with Amgen Inc. (AMGN) to...
Nasdaq News: Markets·8h ago
News Placeholder
More News
News Placeholder
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Labs investigational delta-like ligand 3...
Business Wire·11h ago
News Placeholder
Highline Wealth Partners LLC Sells 4,004 Shares of Amgen Inc. $AMGN
Highline Wealth Partners LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 96.0% during the fourth quarter, according to the company in its most recent disclosure with...
MarketBeat·11h ago
News Placeholder
Nisa Investment Advisors LLC Has $55.22 Million Stake in Amgen Inc. $AMGN
Nisa Investment Advisors LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 168,716 shares of the medical research company's stock after buying an additiona...
MarketBeat·12h ago
News Placeholder
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co.
Meyer Handelman Co. reduced its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 119,231 shares of...
MarketBeat·12h ago
News Placeholder
Amgen Inc. $AMGN Shares Bought by Moody Lynn & Lieberson LLC
Moody Lynn & Lieberson LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 374.0% in the fourth quarter, according to the company in its most recent disclosure with the...
MarketBeat·12h ago
News Placeholder
BTC Capital Management Inc. Sells 4,196 Shares of Amgen Inc. $AMGN
BTC Capital Management Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 38.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,812 shares of the medical research company's stock after sel...
MarketBeat·15h ago
News Placeholder
Amgen Inc. (NASDAQ:AMGN) Given Average Rating of "Hold" by Analysts
Shares of Amgen Inc. (NASDAQ:AMGN - Get Free Report) have been assigned a consensus rating of "Hold" from the thirty brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, fourteen have issued a buy rat...
MarketBeat·16h ago
News Placeholder
FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos Use
FDA flags liver injury risk tied to Amgen Tavneos, citing drug-induced liver injury and rare vanishing bile duct syndrome complications.read more...
Benzinga·1d ago
News Placeholder
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
Teva wins FDA approval for Prolia biosimilar Ponlimsi and secures Xolair biosimilar filing review by the FDA and EMA, strengthening its biosimilars push.
Zacks·1d ago
<
1
2
...
>

Latest AMGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.